These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 17581228

  • 21. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions.
    Ouyang P, Michos ED, Karas RH.
    J Am Coll Cardiol; 2006 May 02; 47(9):1741-53. PubMed ID: 16682298
    [Abstract] [Full Text] [Related]

  • 22. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause?
    Manson JE, Bassuk SS.
    Am J Epidemiol; 2007 Sep 01; 166(5):511-7. PubMed ID: 17646204
    [Abstract] [Full Text] [Related]

  • 23. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research.
    Henderson VW.
    Neuroscience; 2006 Sep 01; 138(3):1031-9. PubMed ID: 16310963
    [Abstract] [Full Text] [Related]

  • 24. [Prevention of cardiovascular risk in menopause women: role of ovarian hormones].
    Rosano GM, Leonardo F, Ricci S, Serra GB, Chierchia SL.
    Ann Ist Super Sanita; 1997 Sep 01; 33(2):199-202. PubMed ID: 9470240
    [Abstract] [Full Text] [Related]

  • 25. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM, Women's Health Initiative.
    Fertil Steril; 2004 Jun 01; 81(6):1498-501. PubMed ID: 15193467
    [Abstract] [Full Text] [Related]

  • 26. Cellular mechanisms underlying the cardiovascular actions of oestrogens.
    Ling S, Komesaroff P, Sudhir K.
    Clin Sci (Lond); 2006 Aug 01; 111(2):107-18. PubMed ID: 16831130
    [Abstract] [Full Text] [Related]

  • 27. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
    Simoncini T, Mannella P, Genazzani AR.
    Recenti Prog Med; 2003 Feb 01; 94(2):51-6. PubMed ID: 12908369
    [Abstract] [Full Text] [Related]

  • 28. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Wenger NK.
    Pediatr Blood Cancer; 2005 Jun 15; 44(7):625-9. PubMed ID: 15747336
    [Abstract] [Full Text] [Related]

  • 29. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Bittner V.
    Expert Opin Pharmacother; 2009 Sep 15; 10(13):2041-53. PubMed ID: 19563274
    [Abstract] [Full Text] [Related]

  • 30. HRT and cardiovascular disease.
    Stevenson JC.
    Best Pract Res Clin Obstet Gynaecol; 2009 Feb 15; 23(1):109-20. PubMed ID: 19095500
    [Abstract] [Full Text] [Related]

  • 31. [Hormone replacement therapy and cardiovascular risk in menopausal women].
    Simon T, Jaillon P.
    Arch Mal Coeur Vaiss; 2001 Feb 15; 94(2):132-8. PubMed ID: 11265551
    [Abstract] [Full Text] [Related]

  • 32. HRT and the cardiovascular system.
    Wren BG.
    Aust Fam Physician; 1992 Mar 15; 21(3):226-9. PubMed ID: 1605760
    [Abstract] [Full Text] [Related]

  • 33. Oestrogen and stroke: the potential for harm as well as benefit.
    Macrae IM, Carswell HV.
    Biochem Soc Trans; 2006 Dec 15; 34(Pt 6):1362-5. PubMed ID: 17073819
    [Abstract] [Full Text] [Related]

  • 34. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen.
    Dubey RK, Imthurn B, Barton M, Jackson EK.
    Cardiovasc Res; 2005 May 01; 66(2):295-306. PubMed ID: 15820198
    [Abstract] [Full Text] [Related]

  • 35. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women.
    McCrohon JA, Adams MR, McCredie RJ, Robinson J, Pike A, Abbey M, Keech AC, Celermajer DS.
    Clin Endocrinol (Oxf); 1996 Oct 01; 45(4):435-41. PubMed ID: 8959082
    [Abstract] [Full Text] [Related]

  • 36. Raloxifene, tamoxifen and vascular tone.
    Leung FP, Tsang SY, Wong CM, Yung LM, Chan YC, Leung HS, Yao X, Huang Y.
    Clin Exp Pharmacol Physiol; 2007 Aug 01; 34(8):809-13. PubMed ID: 17600563
    [Abstract] [Full Text] [Related]

  • 37. [Vascular protection with estrogen. In-vitro and in-vivo effects--mechanisms and clinical implication].
    Barton M, Wright E, Dai-Do D, Yang Z, Espinosa E, Arnet U, Lüscher TF.
    Praxis (Bern 1994); 1997 Jan 28; 86(5):129-37. PubMed ID: 9064730
    [Abstract] [Full Text] [Related]

  • 38. [Evaluation of the cardiovascular impact of hormonal replacement therapy in menopausal women].
    Gaspard UJ.
    J Gynecol Obstet Biol Reprod (Paris); 1996 Jan 28; 25(7):671-6. PubMed ID: 8991899
    [Abstract] [Full Text] [Related]

  • 39. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T, Genazzani AR.
    Climacteric; 2010 Feb 28; 13(1):22-33. PubMed ID: 19938948
    [Abstract] [Full Text] [Related]

  • 40. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J, Barrett-Connor E, Braunwald E, Chesney M, Cohen HJ, Demets D, Dunn L, Dwyer J, Heaney RP, Vogel V, Walters L, Yusuf S.
    Clin Trials; 2007 Feb 28; 4(3):218-34. PubMed ID: 17715247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.